OnCusp Therapeutics Welcomes Dr. Dimitry Nuyten as Chief Medical Officer OnCusp Therapeutics has appointed Dr. Dimitry Nuyten as its Chief Medical Officer, signaling a strategic move to drive clinical development and innovation.

OnCusp Therapeutics Welcomes Dr. Dimitry Nuyten as Chief Medical Officer #United_States #Princeton #OnCusp_Therapeutics #CUSP06 #Dimitry_Nuyten

OnCusp Therapeutics Reveals Promising Phase 1a Results for CUSP06 in Advanced Ovarian Cancer Treatment OnCusp Therapeutics has announced encouraging initial results from its CUSP06 trial, showing potential efficacy in treating advanced ovarian cancer. This innovative ADC displays a promising safety profile.

OnCusp Therapeutics Reveals Promising Phase 1a Results for CUSP06 in Advanced Ovarian Cancer Treatment #United_States #Princeton #Ovarian_Cancer #OnCusp_Therapeutics #CUSP06

OnCusp Therapeutics' CUSP06 Receives Fast Track Status for Ovarian Cancer Treatment OnCusp Therapeutics has achieved Fast Track Designation from the FDA for its innovative CUSP06 treatment aimed at platinum-resistant ovarian cancer patients, accelerating its development.

OnCusp Therapeutics' CUSP06 Receives Fast Track Status for Ovarian Cancer Treatment #United_States #Princeton #FDA_Fast_Track #OnCusp_Therapeutics #CUSP06